Pharma’s new and exciting era of targeted therapeutics has the potential to be a turning point for modern medicine. The buzz has led to a...
Read moreCell Therapies
How the Industry’s Pandemic Response Opened the Door to Therapeutic Opportunities
The biopharma industry was certainly not immune to the turbulence brought about by the COVID-19 pandemic. The pandemic disrupted — and in some cases, stopped completely —...
Gene and Cell Therapy Developers Are Getting Creative to Keep Programs on Track During the Pandemic
Jeanette Young, senior consultant for analytical services at BioTechLogic talks with Tonia Becker, Life Sciences Editor, Macon Raine As it became clear that the COVID-19...
Lessons and Insights into the Korean Biopharmaceutical Market During the COVID-19 Pandemic
Tonia Becker, Life Sciences Editor, Macon Raine talks with BioTechLogic’s Dr. Eileen Choi How is the COVID-19 pandemic affecting the global biopharmaceutical market?...
Process Validation for Expedited Approval Drugs
WHITE PAPER Process Validation and Regulatory Review in the Age of Expedited Approval Drugs This paper explores those dynamics and offers some revised approach suggestions....
Cell Therapies – Overcoming Challenges Within the Regulatory Framework
WHITE PAPER Cell Therapies Come of Age: Overcoming Challenges Within the Regulatory Framework Within the cell therapy arena, regulators, the medical community and industry...
Recent Posts
- Top 25 Biotech Companies of 2024
- The EU Clinical Trials Regulation – Experiences from the First 18 Months
- CMC Expertise Accelerating Biologics Development for 20 Years and Counting
- Strengthening Your Gene Therapy Process Control Strategy
- Designing a Gene Therapy CMC Architecture for the Full Product Lifecycle